SCHEMBL7779560

SCHEMBL7779560

CC(CO[C@]1(Cc2ccccc2)C[C@H]2CC[C@]1(C)C2(C)C)CN(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 1/20 0.46
SLC6A12 P48065 1/20 0.46
SLC6A11 P48066 1/20 0.46
SCN1A P35498 1/20 0.31
SCN2A Q99250 1/20 0.31
SCN3A Q9NY46 1/20 0.31
HSD17B3 P37058 2/20 0.31
OPRL1 P41146 3/20 0.30
CHRM1 P11229 1/20 0.30
DRD2 P14416 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
CHRM3 P20309 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
ADRA1A P35348 1/20 0.30
HRH1 P35367 1/20 0.30
DRD3 P35462 1/20 0.30
KCNH2 Q12809 1/20 0.30
PLA2G1B P04054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7782410 1.00 SLC6A1 (0.46) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
Fumaric Acid SCHEMBL11257527 0.92 SLC6A1 (0.40) SLC6A1SLC6A12SLC6A11DRD2HTR2A
Ramciclane SCHEMBL2108206 0.82 SLC6A1 (0.64) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
SCHEMBL11257896 0.80 SLC6A1 (0.56) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
SCHEMBL7780678 0.80 SLC6A1 (0.56) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
SCHEMBL11252330 0.79 SLC6A1 (0.49) SLC6A1SLC6A12SLC6A11HSD17B3CHRM1
SCHEMBL11253836 0.77 SLC6A1 (0.45) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
SCHEMBL11241358 0.76 SLC6A1 (0.50) SLC6A1SLC6A12SLC6A11HSD17B3CHRM1
SCHEMBL11251756 0.74 SLC6A1 (0.46) SLC6A1SLC6A12SLC6A11SCN1ASCN2A
SCHEMBL11245908 0.73 SLC6A1 (0.45) SLC6A1SLC6A12SLC6A11CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof Exciva GmbH (DE) 2022-10-25 US claimed
EP-0694299-A1 The use of( a) bicycloheptane derivative(s) EGIS GYOGYSZERGYAR RT. (HU) 1996-01-31 EP claimed
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof Exciva GmbH (DE) 2022-10-25 US disclosed
EP-0694299-B1 The use of( a) bicycloheptane derivative(s) EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2001-09-19 EP disclosed
EP-0694299-A1 The use of( a) bicycloheptane derivative(s) EGIS GYOGYSZERGYAR RT. (HU) 1996-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof HTR2A, HTR2C, CYP3A43 SLC6A1 507/4885SLC6A12 1460/4885SLC6A11 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.